PR-619
-
PR-619
structure -
-
CAS No:
2645-32-1
-
Formula:
C7H5N5S2
-
Chemical Name:
PR-619
-
Synonyms:
PR-619;2,6-DiaMino-3,5-dithiocyanopyridine;3,5-dithiocyanatopyridine-2,6-diaMine;Thiocyanic acid, C,C'-(2,6-diamino-3,5-pyridinediyl) ester;2,6-Diamino-3,5-dithiocyanopyridinePR 619;PR 619 2,6-Diamino-3,5-dithiocyanopyridine;2,6-Diaminopyridine-3,5-bis(thiocyanate);PR-619, >=98%
- Categories:
-
CAS No:
Description
PR-619 is a broad-range DUB inhibitor with EC50 of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for USP4, USP8, USP7, USP2, and USP5, respectively.
Characteristics
163
1.3
white to beige
1.6±0.1 g/cm3
210℃
199.3±28.7 °C
1.764
DMSO: soluble5mg/mL (clear solution)
-20°C
Safety Information
NONH for all modes of transport
3
22-37/38-41-43
26-36/37/39
Xn
P261-P280-P305 + P351 + P338
H302-H315-H317-H318-H335
|Danger|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P272, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P310, P312, P321, P330, P332+P313, P333+P313, P362, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
PR-619 Use and Manufacturing
PR 619 is a broad-range DUB inhibitor. A selective and general inhibitior of cellular DUB activity without direct impairment of proteasomal proteolysis. Used in the preparation of thiazolopyridines and bisthiazolopyridines.
Computed Properties
Molecular Weight:223.3
XLogP3:1.3
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:2
Exact Mass:222.99863753
Monoisotopic Mass:222.99863753
Topological Polar Surface Area:163
Heavy Atom Count:14
Complexity:261
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of PR-619
-
US
6 YRS
Business licensed Certified factoryManufactory Supplier of Coenzymes,Inhibito,Enzymes,Zymogens,Substrates
Latest News on PR-619
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4